Fluorescent staining of tumour sections for hypoxia and validated markers in the H22 tumour-carrying mouse model showed that PFH@LSLP enhances anti-tumour effects by reducing hypoxic zones and increasing HIF-1α and CXCR4 expression in PDX HCC tumours. This evidence concerns the gene HIF1A and hepatocellular carcinoma.